Nidec Shares Plunge on Report of $6.3 Billion Impairment Charge 
OpenAI, Anthropic CEOs Summoned to Australia AI Inquiry 
Erste Group Plans Tender Offer to Boost Poland Bank Stake 
Robinhood Chain Token Ring Allegedly Extracts $18.4 Million Across 53 Launches 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
Franklin Templeton Partners With Bybit for Tokenized Fund Collateral 
Pi Network Price Holds $0.087 as Protocol 28 Mainnet Upgrade Nears 
Northern Star Shares Surge After Rejecting Gold Fields Takeover Bid 
OpenAI Investigates Rogue AI Agents After Data Leaks and Security Incidents 
Bitget Restores Withdrawals After $388 Million Security Breach 
TikTok Reaches $100 Million Alabama Settlement Over Child Safety Claims 
Europe’s AI Data Centre Boom Strengthens Case for Nuclear Power 
Citigroup Expands Coinbase Partnership for Stablecoin Payments 
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP 
Strategy Buys 1,665 Bitcoin as BTC Holdings Reach 847,666 
Nissan Targets US Hybrid Growth With Rogue e-Power Launch 
RedotPay Completes Audits as Stablecoin Firm Advances U.S. IPO Plans 
Add as a preferred source on Google
NEW YORK, Oct. 31, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Spectrum Pharmaceuticals, Inc. (“Spectrum Pharmaceuticals”) (NASDAQ:SPPI) between December 16, 2015 and September 16, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Nevada. If you purchased or otherwise acquired Spectrum Pharmaceuticals between December 16, 2015 and September 16, 2016, your rights may be affected by this action. To get more information go to:
http://www.zlk.com/pslra/spectrum-pharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the "FDA") questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants' public statements concerning the Company's business, operations and prospects were materially false and misleading at all relevant times.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
